Celcuity LLC


Prices are adjusted according to historical splits.

Celcuity LLC Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$223.62 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Celcuity LLC had its IPO on 2017-09-20 under the ticker symbol CELC.

The company operates in the Healthcare sector and Biotechnology industry. Celcuity LLC has a staff strength of 45 employees.

Stock update

Shares of Celcuity LLC opened at $10.47 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $10.25 - $10.98, and closed at $10.36.

This is a +0.44% increase from the previous day's closing price.

A total volume of 245,111 shares were traded at the close of the day’s session.

In the last one week, shares of Celcuity LLC have increased by +3.45%.

Celcuity LLC's Key Ratios

Celcuity LLC has a market cap of $223.62 million, indicating a price to book ratio of 3.3317 and a price to sales ratio of 0.

In the last 12-months Celcuity LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-39180172. The EBITDA ratio measures Celcuity LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celcuity LLC’s operating margin was 0% while its return on assets stood at -18.82% with a return of equity of -39.88%.

In Q4, Celcuity LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Celcuity LLC’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celcuity LLC’s profitability.

Celcuity LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0746. Its price to sales ratio in the trailing 12-months stood at 0.

Celcuity LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$175.70 million
Total Liabilities
$6.88 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Celcuity LLC ended 2023 with $175.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $175.70 million while shareholder equity stood at $133.77 million.

Celcuity LLC ended 2023 with $0 in deferred long-term liabilities, $6.88 million in other current liabilities, 21667.00 in common stock, $-96296887.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.57 million and cash and short-term investments were $168.59 million. The company’s total short-term debt was $194,198 while long-term debt stood at $34.98 million.

Celcuity LLC’s total current assets stands at $175.19 million while long-term investments were $0 and short-term investments were $144.02 million. Its net receivables were $0 compared to accounts payable of $2.63 million and inventory worth $0.

In 2023, Celcuity LLC's operating cash flow was $-143985070.00 while its capital expenditure stood at $112044.

Comparatively, Celcuity LLC paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Celcuity LLC stock is currently trading at $10.36 per share. It touched a 52-week high of $14.402 and a 52-week low of $14.402. Analysts tracking the stock have a 12-month average target price of $24.

Its 50-day moving average was $10.88 and 200-day moving average was $10.11 The short ratio stood at 5.82 indicating a short percent outstanding of 0%.

Around 2292.9% of the company’s stock are held by insiders while 5505.8% are held by institutions.

Frequently Asked Questions About Celcuity LLC

The stock symbol (also called stock or share ticker) of Celcuity LLC is CELC

The IPO of Celcuity LLC took place on 2017-09-20

Similar Industry Stocks (Biotechnology)

Last Price
OptiNose (OPTN)
Kubient Inc (KBNTW)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.


16305?36th Avenue North, Minneapolis, MN, United States, 55446